Molecular medicine in staging and restaging of prostate cancer

Dit document is (ook) beschikbaar voor ruilverkeer - alleen door bibliotheken -. [Bestelformulier]

Prostate cancer and its treatment have taken a prominent place in western health care systems. In part this is due to a rising incidence. Consequently, treatment modalities have expanded which leads to increasing demands and costs for surgical and medical treatment. It is expected that the number of patients treated with multi-modality schemes will increase further including local salvage treatment. Patient selection is of utmost importance in order to improve treatment outcomes as well as to limit toxicity of ineffective treatment. Unfortunately, current clinical and morphological imaging has limitations in its use for proper selection of patients for (salvage) treatment. Identifying the localisation and extent of tumour can be cumbersome. The need for imaging the various stages of (recurrent) prostate cancer remains and the potential of molecular imaging using PET has already been proposed by many groups. In this thesis the clinical use of PET is further explored in both initial staging of bone metastases using F-Sodium Fluoride PET. Next we studied the value of bone markers for early detection of metastases. PET was also studied in staging of patients with a biochemical recurrence after external beam radiotherapy and after radical prostatectomy using C-choline PET. To provide insight on the background of the uptake of choline in prostate cancer we studied the correlation between choline uptake and cell proliferation. This is to answer the pending question whether choline is a true marker of proliferation.

Meer informatie in de catalogus
Meer informatie in Picarta